These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 7841541

  • 1. Intracellular doxorubicin kinetics in lymphoma cells and lymphocytes infiltrating the tumor area in vivo: a flow cytometric study.
    Zaleskis G, Ho RL, Diegelman P, Maccubbin D, Ujházy P, Mihich E, Ehrke MJ.
    Oncol Res; 1994; 6(4-5):183-94. PubMed ID: 7841541
    [Abstract] [Full Text] [Related]

  • 2. Immunological responses critical to the therapeutic effects of adriamycin plus interleukin 2 in C57BL/6 mice bearing syngeneic EL4 lymphoma.
    Ho RL, Maccubbin DL, Ujházy P, Zaleskis G, Eppolito C, Mihich E, Ehrke MJ.
    Oncol Res; 1993; 5(9):363-72. PubMed ID: 8038457
    [Abstract] [Full Text] [Related]

  • 3. Development of a safe and effective adriamycin plus interleukin 2 therapy against both adriamycin-sensitive and -resistant lymphomas.
    Ho RL, Maccubbin D, Zaleskis G, Krawczyk C, Wing K, Mihich E, Ehrke MJ.
    Oncol Res; 1993; 5(9):373-81. PubMed ID: 8038458
    [Abstract] [Full Text] [Related]

  • 4. Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting.
    Etrych T, Chytil P, Mrkvan T, Sírová M, Ríhová B, Ulbrich K.
    J Control Release; 2008 Dec 18; 132(3):184-92. PubMed ID: 18534705
    [Abstract] [Full Text] [Related]

  • 5. [Relationship between sensitivity of tumor cells to chemotherapeutic agent in vivo and in vitro: experiment with mouse lymphoma cells].
    Li CG, Li ML, Shu XH, Jia YJ, Liu YJ, Li M.
    Zhonghua Yi Xue Za Zhi; 2007 Jun 12; 87(22):1576-8. PubMed ID: 17785116
    [Abstract] [Full Text] [Related]

  • 6. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
    Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A.
    Clin Cancer Res; 2000 May 12; 6(5):1949-57. PubMed ID: 10815920
    [Abstract] [Full Text] [Related]

  • 7. Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole.
    Desai PB, Duan J, Sridhar R, Damle BD.
    Methods Find Exp Clin Pharmacol; 1997 May 12; 19(4):231-9. PubMed ID: 9228648
    [Abstract] [Full Text] [Related]

  • 8. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, Levy L, Atkinson EN, Zhang HZ, Melichar B, Patenia R, Templin S, Scott W, Platsoucas CD.
    Clin Cancer Res; 2000 Jun 12; 6(6):2268-78. PubMed ID: 10873077
    [Abstract] [Full Text] [Related]

  • 9. Mechanisms of the in vivo resistance to adriamycin and modulation by calcium channel blockers in mice.
    Yin MB, Bankusli I, Rustum YM.
    Cancer Res; 1989 Sep 01; 49(17):4729-33. PubMed ID: 2758408
    [Abstract] [Full Text] [Related]

  • 10. Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo.
    Yoshimoto Y, Kawada M, Ikeda D, Ishizuka M.
    Int Immunopharmacol; 2005 Feb 01; 5(2):281-8. PubMed ID: 15652759
    [Abstract] [Full Text] [Related]

  • 11. Screening of biochemical modulator by tumor cell permeability of doxorubicin.
    Sadzuka Y, Hatakeyama H, Daimon T, Sonobe T.
    Int J Pharm; 2008 Apr 16; 354(1-2):63-9. PubMed ID: 18054183
    [Abstract] [Full Text] [Related]

  • 12. Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2.
    Vallera DA, Taylor PA, Aukerman SL, Blazar BR.
    Cancer Res; 1993 Sep 15; 53(18):4273-80. PubMed ID: 8364923
    [Abstract] [Full Text] [Related]

  • 13. Doxorubicin and cyclosporin A affect murine lymphoid cells expressing different antigenic determinants.
    Zaleskis G, Verstovsek S, Tzai TS, Mihich E, Ehrke MJ.
    Oncol Res; 1995 Sep 15; 7(6):307-15. PubMed ID: 8527865
    [Abstract] [Full Text] [Related]

  • 14. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
    Kisara S, Furusawa S, Murata R, Ogata M, Hikichi N, Takayanagi Y, Sasaki K.
    Oncol Res; 1995 Sep 15; 7(3-4):191-200. PubMed ID: 8555653
    [Abstract] [Full Text] [Related]

  • 15. Overcoming drug-resistant cancer by a newly developed copper chelate through host-protective cytokine-mediated apoptosis.
    Mookerjee A, Mookerjee Basu J, Dutta P, Majumder S, Bhattacharyya S, Biswas J, Pal S, Mukherjee P, Raha S, Baral RN, Das T, Efferth T, Sa G, Roy S, Choudhuri SK.
    Clin Cancer Res; 2006 Jul 15; 12(14 Pt 1):4339-49. PubMed ID: 16857809
    [Abstract] [Full Text] [Related]

  • 16. Tumor sponge implantation: an in vivo method for studying syngeneic, primary antitumor lymphocyte responses.
    Vallera DA, Mentzer SJ, Maizel SE.
    Cancer Res; 1982 Feb 15; 42(2):397-404. PubMed ID: 7055792
    [Abstract] [Full Text] [Related]

  • 17. Protective effect of NK1.1(+) T cells as well as NK cells against intraperitoneal tumors in mice.
    Kawamura T, Seki S, Takeda K, Narita J, Ebe Y, Naito M, Hiraide H, Abo T.
    Cell Immunol; 1999 May 01; 193(2):219-25. PubMed ID: 10222065
    [Abstract] [Full Text] [Related]

  • 18. Doxorubicin-induced DNA degradation in murine thymocytes.
    Zaleskis G, Berleth E, Verstovsek S, Ehrke MJ, Mihich E.
    Mol Pharmacol; 1994 Nov 01; 46(5):901-8. PubMed ID: 7969078
    [Abstract] [Full Text] [Related]

  • 19. Modulatory effects of tamoxifen and recombinant human alpha-interferon on doxorubicin resistance.
    Kang Y, Perry RR.
    Cancer Res; 1993 Jul 01; 53(13):3040-5. PubMed ID: 8100483
    [Abstract] [Full Text] [Related]

  • 20. Isolation and characterization of a metastatic Eb-like tumor variant highly responsive to interleukin (IL)-2 and to combination cytokine therapy with IL-2/IL-1 beta and IL-1 beta/interferon-alpha/beta.
    Gabriele L, Proietti E, Greco G, Venditti M, Gresser I, Schirrmacher V, Von Hoegen P, Testa U, Modesti A, Cianfriglia M.
    Invasion Metastasis; 1993 Jul 01; 13(3):147-62. PubMed ID: 8112975
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.